Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Brada, Michael; Hoang-Xuân, Khê; Rampling, Roy; Dietrich, Pierre‐Yves; Dirix, Luc; Macdonald, David R.; Heimans, Jan J.; Zonnenberg, Bernard A.; Bravo‐Marques, J. M.; Henriksson, Roger; Stupp, Roger; Yue, Nancy Chang; Bruner, Janet M.; Dugan, Margaret; S, Rao; Zaknoen, Sara

doi:10.1023/a:1008382516636

Cited by 337 publications

(199 citation statements)

References 26 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…A single-arm phase II trial in 126 patients led to a PFS-6 rate of 18% [45]. Both trials used a schedule of TMZ 150-200 mg/m 2 for 5 out of 28 days.…”

Section: Temozolomide Monotherapy and Combination Regimensmentioning

confidence: 99%

Therapeutic options in recurrent glioblastoma—An update

Seystahl

Wick

Weller

2016

Critical Reviews in Oncology/Hematology

177

142

View full text Add to dashboard Cite

show abstract

“…A single-arm phase II trial in 126 patients led to a PFS-6 rate of 18% [45]. Both trials used a schedule of TMZ 150-200 mg/m 2 for 5 out of 28 days.…”

Section: Temozolomide Monotherapy and Combination Regimensmentioning

confidence: 99%

Therapeutic options in recurrent glioblastoma—An update

Seystahl

Wick

Weller

2016

Critical Reviews in Oncology/Hematology

177

142

View full text Add to dashboard Cite

show abstract

“…The prognosis at time of relapse is even worse (Finlay et al, 1995;Nieder et al, 2000;Brada et al, 2001;Tamber and Rutka, 2003;Rich et al, 2004). However, new treatment strategies are under development, one of them being immune therapy.…”

mentioning

confidence: 99%

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

Rutkowski¹,

Vleeschouwer²,

et al. 2004

View full text Add to dashboard Cite

Patients with relapsed malignant glioma have a poor prognosis. We developed a strategy of vaccination using autologous mature dendritic cells loaded with autologous tumour homogenate. In total, 12 patients with a median age of 36 years (range: 11 -78) were treated. All had relapsing malignant glioma. After surgery, vaccines were given at weeks 1 and 3, and later every 4 weeks. A median of 5 (range: 2 -7) vaccines was given. There were no serious adverse events except in one patient with gross residual tumour prior to vaccination, who repetitively developed vaccine-related peritumoral oedema. Minor toxicities were recorded in four out of 12 patients. In six patients with postoperative residual tumour, vaccination induced one stable disease during 8 weeks, and one partial response. Two of six patients with complete resection are in CCR for 3 years. Tumour vaccination for patients with relapsed malignant glioma is feasible and likely beneficial for patients with minimal residual tumour burden.

show abstract

“…It is licensed for the treatment of recurrent malignant glioma (glioblastoma multiforme and anaplastic astrocytoma) (Yung et al, 1999(Yung et al, , 2000Brada et al, 2001). The 35% response rate in WHO grade III astrocytoma (anaplastic astrocytoma) (Yung et al, 1999) in comparison to 6 -8% response rate in grade IV tumours (glioblastoma multiforme) (Yung et al, 2000;Brada et al, 2001) suggests a possible trend of increasing efficacy in lower grade tumours previously noted for nitrosourea-containing chemotherapy (Rajan et al, 1994). On the basis of excellent tolerance and potential efficacy of temozolomide in lower grade tumours, we evaluated temozolomide as the primary treatment following surgery in patients with grade II glial tumours in a single arm phase II study.…”

mentioning

confidence: 99%

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

et al. 2004

View full text Add to dashboard Cite

Assessment of low-grade glioma treatment response remains as much of a challenge as the treatment itself. Proton magnetic resonance spectroscopy ( 1 H-MRS) and imaging were incorporated into a study of patients receiving temozolomide therapy for lowgrade glioma in order to evaluate and monitor tumour metabolite and volume changes during treatment. Patients (n ¼ 12) received oral temozolomide (200 mg m À2 day À1 ) over 5 days on a 28-day cycle for 12 cycles. Response assessment included baseline and three-monthly magnetic resonance imaging studies (pretreatment, 3, 6, 9 and 12 months) assessing the tumour size. Short (TE (echo time) ¼ 20 ms) and long (TE ¼ 135 ms) echo time single voxel spectroscopy was performed in parallel to determine metabolite profiles. The mean tumour volume change at the end of treatment was À33% (s.d. ¼ 20). The dominant metabolite in long echo time spectra was choline. At 12 months, a significant reduction in the mean choline signal was observed compared with the pretreatment (P ¼ 0.035) and 3-month scan (P ¼ 0.021). The reduction in the tumour choline/water signal paralleled tumour volume change and may reflect the therapeutic effect of temozolomide.

show abstract

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Abstract: Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM. The use of this drug should be explored further in an adjuvant setting and in combination with other agents.

Cited by 337 publications

References 26 publications

Therapeutic options in recurrent glioblastoma—An update

Therapeutic options in recurrent glioblastoma—An update

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

Contact Info

Product

Resources

About